NCT04261387View on ClinicalTrials.gov

LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 30, 2021

Primary Completion Date

June 16, 2022

Study Completion Date

July 15, 2022

Conditions
Radiation Dermatitis
Interventions
DRUG

LUT014 Gel

Topical application qd for 28 days

DRUG

Placebo for LUT014 Gel

Matching placebo for qd topical application for 28 days

Trial Locations (2)

31901

Columbus Regional Research Institute, Llc, Columbus

71103

Willis-Knighton Cancer Center, Shreveport

Sponsors

Lead Sponsor

Lutris Pharma Ltd.
All Listed Sponsors
lead

Lutris Pharma Ltd.

INDUSTRY

NCT04261387 - LUT014 for the Treatment of Radiation Induced Dermatitis in Breast Cancer Patients | Biotech Hunter | Biotech Hunter